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Background andObjective:Malignant pleural effusion (MPE) often results in debilitating
symptoms. Relief of dyspnoea and improvement in quality of life can be achieved with
either talc pleurodesis or insertion of an indwelling tunneled pleural catheter (IPC). The
former requires a lengthy hospital stay and the latter is associated with lower pleurodesis
rates. In response to limited hospital bed capacity, we developed a pragmatic approach
in managing MPE by combining thoracoscopic talc poudrage and insertion of IPC into a
single day case procedure. We present data on the safety and efficacy of this approach.
Methods: Patients who had undergone the abovementioned procedure between 2017
and 2020 were analyzed. Demographic data, hospital length of stay (LOS), histological
diagnosis, rates of pleurodesis success and procedural related complications were
collated. Patients were followed-up for 6 months.
Results: Forty-five patients underwent the procedure. Mean age was 68.5 ± 10.4
years and 56% were male. Histological diagnosis was achieved in all cases. 86.7% of
patients were discharged on the day of the procedure. Median LOS was 0 (IQR 0–0)
days. Successful pleurodesis was attained in 77.8% at 6-month follow-up. No procedure
related deaths or IPC related infections were recorded.
Conclusion: Ambulatory thoracoscopic poudrage and IPC insertion is a safe
and effective option in the management of MPE. All patients received a definitive
pleural intervention with 77.8% pleurodesis success at 6-months and majority of
them discharged on the same day. Future randomized trials are required to confirm
these findings.
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INTRODUCTION
Malignant pleural effusion (MPE) affects up to 15% of patients with cancer (1). MPE is usually the
result of malignant infiltration of the pleural and commonly causes debilitating symptoms such as
dyspnoea, cough, and chest pain. The goal in managing MPE is to relieve dyspnoea and improve
quality of life (2). This is often achieved with chemical pleurodesis using medical graded talc, or
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an indwelling tunneled pleural catheter (IPC). Talc pleurodesis
is highly effective but requires 4–6 days hospitalization (3, 4).
In contrast, IPCs are routinely inserted as day-case procedures
however confer a much lower pleurodesis rate even when
used in combination with talc (5, 6). Furthermore, there is an
inherent risk of infection with IPCs (7), as well as the cost and
inconvenience associated with community drainages (8).
In response to the increasing number of patients with MPE
seen at our institution and the challenges with hospital bed
capacity, we developed a pragmatic approach in the diagnosis
and management of MPE by combining medical thoracoscopy
with talc poudrage and insertion of IPC into a single day case
procedure. In doing so, we take advantage of both management
strategies while minimizing their disadvantages.
In this paper, we retrospectively describe our experience and
outcomes of this approach.
METHODS
Patients
In this retrospective chart-based study, patients who had
undergone the above-mentioned procedure between March 2017
and March 2020 for diagnosis or management of a suspected or
proven MPE were identified. Patients were ≥18 years old, had
an Eastern Cooperative Oncology Group performance status of
≤2, an expected survival of >2 months, and judged to be able
to tolerate the procedure under conscious sedation. Lung re-
expansion was confirmed on chest x-ray (CXR) post-therapeutic
aspiration in 93% (42/45) of patients. The remaining 7% (3
patients) underwent the procedure upfront. Clinical data analysis
was approved by Addenbrooke’s Hospital Institutional Review
Board (ID3673).
Procedure
Patients underwent ultrasound guided rigid thoracoscopy with
a single 7mm port in a standard bronchoscopy suite by a
pulmonologist. All patients received midazolam for sedation,
fentanyl for analgesia, and local anesthesia. Pleural fluid was
evacuated before biopsies were performed followed by placement
of a Rocket R© IPC via a new incision. Steritalc R© (Novatech
SA, France) 3 g was insufflated into the pleural cavity. A 20 Fr
intercostal drain was placed through the port site and connected
to 4 kPa suction. The IPC was not used in the immediate
post-procedure period. Patients were transferred to the recovery
area for monitoring and a CXR was performed 1–2 h after
the procedure. Intercostal drain was removed if CXR showed
resolution of procedure-induced pneumothorax and no clinical
evidence of air leak. Patients were discharged if clinically stable
with follow-up at their local center. IPC was drained daily
for the first 2 days and thrice a week subsequently or as
determined by the treating clinician. All patients also had a
routine clinical review 2–3 days after their procedure, with any
further appointments at the discretion of the local team or at
the patient’s request, usually only if there are concerns with the
IPC e.g., low or no output, pain, suspected blockage or infection.
Patients were followed for 6 months post-procedure.
Data Collected
Data collected included demographics, hospital length of stay
(LOS), histological diagnosis, amount of procedural sedation,
and rates of successful pleurodesis at 3- and 6-months. Patients’
survival status were determined from medical records or
telephone call 6 months post-procedure. Successful pleurodesis
was defined as the removal of the IPC which occurred if <50ml
of fluid was drained on three consecutive occasions and CXR
showed <25% opacification of the appropriate hemithorax due
to suspected fluid. Thoracic ultrasonography was used to assess
the absence of lung sliding and confirm CXR findings. Patients
requiring aspiration of >100ml of fluid; chest drain or IPC
insertion for fluid management; and thoracoscopy of any kind
on the same side as the IPC after its removal, or who declined or
died before these procedures could be performed were classified
as failed pleurodesis. Procedural complications and IPC related
infections were noted. Data were summarized using mean,
median, standard deviation and interquartile ranges, or number
(%). Six-month survival was calculated using the Kaplan-Meier
method. Statistical analyses were performed using IBM R© SPSS R©
Statistics 26.
TABLE 1 | Patient characteristics and summary of results.
Characteristics Value
Demographics




Midazolam (mg) 3.7 ± 1.3









Fibrinous pleuritis 1 (2.2)
Total cases 45
Day case 39 (86.7)
Required admission 6 (13.3)
Air leak 3 (50)
Hypotension 2 (33.3)
Pneumonia 1 (16.7)
Length of stay (days)
Overall 0 (IQR 0–0)
Admitted cases 2.5 (IQR 1–5.5)
Pleurodesis success
3 months 32 (71.1)
6 months 35 (77.8)
Values are presented as mean ± standard deviation, median (IQR), or number (%).
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FIGURE 1 | Kaplan Meier survival curve of 45 patients after combined thoracoscopic procedure.
RESULTS
Forty-five patients were included in the study. Mean age was 68.5
± 10.4 years and 25 (56%) were male. An average of 3.7± 1.3mg
of midazolam and 101.7 ± 26.9 mcg of fentanyl were required
for procedural sedation and analgesia. Pleural malignancy was
histologically confirmed in all but one patient who had fibrinous
pleuritis. The most common malignancy was mesothelioma (n
= 10), followed by lung (n = 9) and breast cancer (n = 9).
Thirty-nine (86.7%) patients spent a mean of 298.9 ± 96.7min
in recovery prior to discharge. Six (13.3%) required admission
for the following reasons: 3 (50%) persistent air leak; 2 (33.3%)
hypotension; 1 (16.7%) pneumonia. Median LOS was 0 (IQR 0–
0) days, and ranged from 1 to 9 days with a median of 2.5 (IQR
1–5.5) days in those admitted (Table 1).
IPC was removed at a median of 20 (IQR 13–48) days.
Successful pleurodesis was achieved in 32 (71.1%) patients
at 3-month and 35 (77.8%) patients at 6-month follow-up.
Between 3- and 6-months, one patient who had previously
achieved pleurodesis had a recurrence of the pleural effusion
and was re-classified as pleurodesis failure. In the same time
period, a further 4 patients had achieved successful pleurodesis
(Table 1). Fourteen (31.1%) patients died from progression of
malignancy within 6 months post-procedure (Figure 1). There
were no procedure related deaths or IPC related complications
(infections, blockages, dislodgements, or catheter fractures
on removal).
DISCUSSION
Current guidelines recommend talc pleurodesis or IPC in the
management of MPE (1, 2). While the recent TAPPS trial showed
talc poudrage to be similar in efficacy to talc slurry in achieving
pleurodesis (78 vs. 76% at 90 days, 71 vs. 72% at 180 days), mean
LOS was 5–6 days (3). Conversely, IPCs are routinely inserted in
an outpatient setting and while effective at relieving dyspnoea,
achieve much lower auto-pleurodesis rates despite addition of
talc (43 vs. 23% at 35 days), or aggressive drainage (47 vs. 24%
at 12 weeks) (5, 9). Additional disadvantages of an IPC-centric
strategy include the inconvenience of community drainages, risk
of IPC related infections, and cost of drainage bottles (10).
In this study, we demonstrated a safe and effective
approach in the ambulatory management of MPE by combining
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thoracoscopic poudrage and IPC insertion into a single day-
case procedure. Our pleurodesis success rates of 71.1 and 78.8%
at 3 and 6-months compare well with TAPPS, and are higher
than in trials utilizing IPCs. Furthermore, 86.7% of patients were
safely discharged on the same day, reducing reliance on hospital
bed capacity which may be severely limited in situations such
as the coronavirus pandemic. The short LOS is also likely to
be important to patients given the limited median survival for
individuals with MPE (1). Importantly, all patients also received
a definitive pleural intervention.
To our knowledge, only three other studies have examined
combination strategies similar to ours. In a pilot study of 30
patients, Reddy et al. described a rapid pleurodesis protocol
and demonstrated a 3.19-day mean hospital length of stay
with a 92% pleurodesis success rate at 6 months and universal
improvement in dyspnoea and quality of life scores (11). A
subsequent retrospective review of an additional 29 patients who
underwent the same rapid pleurodesis protocol after the initial
trial ended recorded a median LOS of 2 days and a successful
pleurodesis rate of 79% although the duration of follow-up
was unclear (12). A separate small study by Boujaoude et al.
involving 29 patients reported a 92% pleurodesis success rate
at 1 month and a median duration of hospitalization of 3 days
as well as improvement in dyspnoea scores (13). Compared
to our approach, patients in these three studies were routinely
admitted post-procedure and underwent aggressive drainage of
their IPC (7 drainages in the first 3 days followed by daily
drainage in Reddy et al., and daily drainages in Krochmal et
al. and Boujaoude et al.), a resource intensive and burdensome
process. Crucially, patients who died were excluded from the
final analysis. Nevertheless, these findings support the safety and
efficacy of combination approaches.
Our study was limited by its retrospective design and small
sample size. Moreover, despite using ultrasound to assess for
evidence of pleurodesis, a validated protocol such as that
published by Chaddha et al. was not utilized (14). Consequently,
the possibility that the resolution of effusion was due to disease
control could not be excluded and future trials should be
designed to address these factors. Thirdly, although all patients
reported subjective improvement in dyspnoea and quality of life
at follow-up, these were not objectively measured.
CONCLUSION
This study highlights the safety, feasibility, and efficacy
of a pragmatic one-stop approach in the diagnosis and
management of MPE. Future randomized trials comparing
this approach with standard talc pleurodesis are required to
confirm these findings. Health economic data will also be
of interest.
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